title: The Protective Role of Phenolic Compounds Against Doxorubicin-induced Cardiotoxicity: A Comprehensive Review.
abstract: Although doxorubicin (DOX) is among the most widely used anticancer agents, its clinical application is hampered owing to its cardiotoxicity. Adjuvant therapy with an antioxidant has been suggested as a promising strategy to reduce DOX-induced adverse effects. In this context, many phenolic compounds have been reported to protect against DOX-induced cardiotoxicity. The cardioprotective effects of phenolic compounds are exerted via multiple mechanisms including inhibition of reactive oxygen species generation, apoptosis, NF-κB, p53, mitochondrial dysfunction, and DNA damage. In this review, we present a summary of the in vitro, in vivo, and clinical findings on the protective mechanisms of phenolic compounds against DOX-induced cardiotoxicity.
authors.affiliation: a Department of Pharmacodynamy and Toxicology , Faculty of Pharmacy, Mashhad University of Medical Sciences , Mashhad , Iran.
authors.forename: Kamal
authors.initials: K
authors.lastname: Razavi-Azarkhiavi
authors.affiliation: b Biotechnology Research Center and School of Pharmacy, Mashhad University of Medical Sciences , Mashhad , Iran.
authors.forename: Milad
authors.initials: M
authors.lastname: Iranshahy
authors.affiliation: c Biotechnology Research Center, Mashhad University of Medical Sciences , Mashhad , Iran.
authors.forename: Amirhossein
authors.initials: A
authors.lastname: Sahebkar
authors.affiliation: d Department of Pharmacodynamy and Toxicology , Faculty of Pharmacy, Mashhad University of Medical Sciences , Mashhad , Iran.
authors.forename: Kobra
authors.initials: K
authors.lastname: Shirani
authors.affiliation: e Department of Pharmacodynamy and Toxicology , Faculty of Pharmacy, Mashhad University of Medical Sciences , Mashhad , Iran.|f Pharmaceutical Research Center and Pharmacy School, Mashhad University of Medical Sciences.
authors.forename: Gholamreza
authors.initials: G
authors.lastname: Karimi
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000737:chemistry; D000975:Antioxidants / Q000009:adverse effects / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D066126:Cardiotoxicity / Q000378:metabolism / Q000517:prevention & control*; D019587:Dietary Supplements / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D005419:Flavonoids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008955:Models, Cardiovascular; D010636:Phenols / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000903:Antibiotics, Antineoplastic; D000975:Antioxidants; D002316:Cardiotonic Agents; D005419:Flavonoids; D010636:Phenols; D004317:Doxorubicin